Key statistics
On Friday, Eupraxia Pharmaceuticals Inc (EPRX:NAQ) closed at 3.49, 58.64% above the 52 week low of 2.20 set on Oct 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.49 |
---|---|
High | 3.49 |
Low | 3.27 |
Bid | 3.20 |
Offer | 5.48 |
Previous close | 3.37 |
Average volume | 38.51k |
---|---|
Shares outstanding | 35.62m |
Free float | 30.47m |
P/E (TTM) | -- |
Market cap | 168.49m CAD |
EPS (TTM) | -1.38 CAD |
Data delayed at least 15 minutes, as of Nov 22 2024 20:58 GMT.
More ▼
Press releases
- Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
- Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
- Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
- Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
- Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
- Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
- Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
- Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
- Eupraxia Pharmaceuticals Strengthens Senior Management Team
More ▼